VEGF Antibody Reduces Eye Neovascularization in Rats
Author Information
Author(s): Geisen P., Peterson L. J., Martiniuk D., Uppal Ahbineet, Saito Y., Hartnett M. Elizabeth
Primary Institution: University of North Carolina at Chapel Hill
Hypothesis
Does a neutralizing antibody to VEGF reduce intravitreous neovascularization without interfering with ongoing retinal vascularization?
Conclusion
The 50 ng dose of VEGF antibody significantly reduced intravitreous neovascularization without affecting ongoing retinal vascularization in a rat model of retinopathy of prematurity.
Supporting Evidence
- Both 25 ng and 50 ng doses of VEGF antibody significantly reduced IVNV at p18.
- The 50 ng dose sustained the inhibitory effect on IVNV at p25.
- There was no significant difference in avascular/total retinal area between treated and control groups at p18.
Takeaway
This study found that a special medicine can help stop bad blood vessels from growing in the eyes of baby rats without hurting the good blood vessels that are still growing.
Methodology
Newborn rats were treated with a VEGF antibody or control and then analyzed for neovascularization and retinal development at different time points.
Limitations
The study was conducted in a rat model, which may not fully replicate human conditions.
Participant Demographics
Newborn Sprague-Dawley rats
Statistical Information
P-Value
p=0.003
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website